The Role of Postoperative Radiotherapy in Carcinoma of the Endometrium

Clinical Oncology

Volumn 20, Issue 6, 2008, Pages 457-462

  Kong, A ^a   Powell, M ^b   Blake, P ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; endometrial carcinoma; external beam radiotherapy; lymphadenectomy; vaginal vault brachytherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MEDROXYPROGESTERONE ACETATE; PACLITAXEL; TAMOXIFEN;

ADJUVANT THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; LEUKOPENIA; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PAPILLARY CARCINOMA; PELVIS LYMPHADENECTOMY; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS;

ANTINEOPLASTIC AGENTS; BRACHYTHERAPY; CARCINOMA; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; LYMPH NODE EXCISION; NEOPLASM STAGING; POSTOPERATIVE CARE; PROGNOSIS; RADIOTHERAPY, ADJUVANT; TIME FACTORS;

EID: 46149126147     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2008.03.011     Document Type: Article

References (31)

1. Pisani P., Bray F., and Parkin D.M. Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97 1 (2002) 72-81
2. Gallup D.G., and Stock R.J. Adenocarcinoma of the endometrium in women 40 years of age or younger. Obstet Gynecol 64 3 (1984) 417-420
3. Rose P.G. Endometrial carcinoma. N Engl J Med 335 9 (1996) 640-649
4. Kucera H., Vavra N., and Weghaupt K. Benefit of external irradiation in pathologic stage I endometrial carcinoma: a prospective clinical trial of 605 patients who received postoperative vaginal irradiation and additional pelvic irradiation in the presence of unfavorable prognostic factors. Gynecol Oncol 38 1 (1990) 99-104
5. Lybeert M.L., van Putten W.L., Brolmann H.A., and Coebergh J.W. Postoperative radiotherapy for endometrial carcinoma. Stage I. Wide variation in referral patterns but no effect on long-term survival in a retrospective study in the southeast Netherlands. Eur J Cancer 34 4 (1998) 586-590
6. Farias-Eisner R.P., and Berek J.S. Gynecologic cancers. Manual of clinical oncology. 4th edn (2000), Lippincott Williams and Wilkins, Philadelphia
7. Greene F.L., Page D.L., Fleming I.D., et al. AJCC cancer staging manual. 6th edn (2002), Springer, Berlin
8. DiSaia P.J., Creasman W.T., Boronow R.C., and Blessing J.A. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol 151 8 (1985) 1009-1015
9. Eltabbakh G.H., Piver M.S., Hempling R.E., and Shin K.H. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys 38 2 (1997) 373-380
10. Keys H.M., Roberts J.A., Brunetto V.L., et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 3 (2004) 744-751
11. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 9213 (2000) 1404-1411
12. Creutzberg C.L. Lymphadenectomy in apparent early-stage endometrial carcinoma: do numbers count?. J Clin Oncol 23 16 (2005) 3653-3655
13. Kitchener HC, RC, Swart AMC, Amos CL. A study in the treatment of endometrial cancer: a randomised trial of lymphadenectomy in the treatment of endometrial cancer. In: 14th International meeting of the European society of gynaecological oncology, Instanbul, 28 September 2005.
14. Fujimoto T., Nanjyo H., Nakamura A., et al. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol 107 2 (2007) 253-259
15. Aalders J., Abeler V., Kolstad P., and Onsrud M. Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients. Obstet Gynecol 56 4 (1980) 419-427
16. Soderini A., AJ, and Sardi J.E. Role of adjuvant radiotherapy (RT) in intermediate risk (1b G2-3-1C) endometrioid carcinoma (EC) after extended staging surgery (ESS). Preliminary reports of a randomised trial. Int J Gynecol Cancer 13 Suppl 1 (2003) [abstract P0147:78]
17. Kong A., Simera I., Collingwood M., Williams C., and Kitchener H. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann Oncol 18 10 (2007) 1595-1604
18. Piver M.S., Yazigi R., Blumenson L., and Tsukada Y. A prospective trial comparing hysterectomy, hysterectomy plus vaginal radium, and uterine radium plus hysterectomy in stage I endometrial carcinoma. Obstet Gynecol 54 1 (1979) 85-89
19. Morrow C.P., Bundy B.N., Kurman R.J., et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40 1 (1991) 55-65
20. Creasman W.T., Morrow C.P., Bundy B.N., Homesley H.D., Graham J.E., and Heller P.B. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer 60 Suppl 8 (1987) 2035-2041
21. Maggi R., Lissoni A., Spina F., et al. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 95 3 (2006) 266-271
22. Dunton C.J., Pfeifer S.M., Braitman L.E., Morgan M.A., Carlson J.A., and Mikuta J.J. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 41 2 (1991) 113-116
23. Burke T.W., Stringer C.A., Morris M., et al. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide. Gynecol Oncol 40 3 (1991) 264-267
24. Aapro M.S., van Wijk F.H., Bolis G., et al. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 14 3 (2003) 441-448
25. Thigpen J.T., Brady M.F., Homesley H.D., et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 22 19 (2004) 3902-3908
26. De Palo G., Mangioni C., Periti P., Del Vecchio M., and Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 29A 8 (1993) 1133-1140
27. Thigpen J.T., Brady M.F., Alvarez R.D., et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 17 6 (1999) 1736-1744
28. Thigpen T., Brady M.F., Homesley H.D., Soper J.T., and Bell J. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 19 2 (2001) 364-367
29. Whitney C.W., Brunetto V.L., Zaino R.J., et al. Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92 1 (2004) 4-9
30. Creutzberg C.L., van Putten W.L., Warlam-Rodenhuis C.C., et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol 22 7 (2004) 1234-1241
31. Kwon J.S., Abrams J., Sugimoto A., and Carey M.S. Is adjuvant therapy necessary for Stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?. Int J Gynecol Cancer (2007) in press